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Abstract
Background: To analyze the results of repeat selective laser trabeculoplasty (SLT).
Methods: Inclusion criteria: participants with primary or secondary open-angle glaucoma (excluding uveitic) who
had undergone SLT 360° (SLT 1) with diminution of response over time followed by repeat SLT 360° (SLT 2). Six
months of follow-up were required and at least 6 months in between SLT 1 and 2. The main outcome measures
were IOP reduction at 6 and 12 months and a comparison of the response between SLT 1 and 2.
Results: One hundred thirty-seven patients met the inclusion criteria. If only one eye had repeat treatment, that eye
was chosen; if both eyes qualified, one was chosen at random. The baseline intraocular pressure (IOP) for SLT 1 = 20.3
+/− 5.2 mmHg and SLT 2 = 19.4 +/− 5.0 was reduced to 16.4 +/− 3.9 and 16.7 +/− 4.7 at 1 year, respectively (p < .001).
Medication use was not significantly changed, and was 2.2 +/− 1.2 at baseline for SLT 1 and 2.1 +/− 1.3 for SLT 2, and
at 1 year was 1.9 +/− 1.3 and 2.2 +/− 1.2, respectively. A subanalysis of 62 patients matched for equivalent baselines
showed a baseline IOP = 18.7 +/− 3.8 for SLT 1 and 18.7 +/− 3.5 for SLT 2, reduced to 16.0 +/− 4.3 and 15.3 +/− 3.8 at
1 year (p < .001).
Conclusion: Repeat SLT laser (360-degree treatment, followed by a loss of effect over time, then a second 360-degree
treatment) in this population resulted in IOP lowering similar to that of the initial treatment.
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Background
Laser trabeculoplasty has been employed as initial,
adjunct or replacement therapy to lower intraocular
pressure (IOP) in patients with open-angle glaucoma
(OAG). The original procedure was described using
argon laser (major peaks at 488 and 514 nm). Laser tra-
beculoplasty has been used to successfully lower the IOP
and slow visual field progression in several multicenter
randomized trials, notably the Early Manifest Glaucoma
Trial [1] and the Advanced Glaucoma Intervention
Study [2]. The Glaucoma Laser Trial showed that in pa-
tients with newly diagnosed open-angle glaucoma, argon
laser trabeculoplasty (ALT) was at least as effective as
initial treatment with timolol maleate 0.5 %, even after
7 years [3, 4]. However, ALT produces significant tissue
disruption and coagulative damage to the trabecular
meshwork, possibly contributing to the limited success
rates reported after retreatment [5, 6]. Indeed, repeated
treatment of the angle with argon laser will eventually
lead to synechial angle closure and a decrease in outflow
facility. Some very preliminary evidence suggested that
the inflammation induced by trabeculoplasty could also
lead to failure of subsequent trabeculectomy because of
increased scarring [7]. This, coupled with the fact that
most patients eventually ended up on medications, led
to the failure of acceptance of ALT as primary glaucoma
therapy. Most physicians in the United States main-
tained the algorithm of maximum tolerated medications
first, then laser trabeculoplasty, and finally filtration
surgery.
The treatment algorithm may be changing with the
use of selective laser trabeculoplasty (SLT), approved by
the FDA in March 2001 for the treatment of OAG.
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Using the 532 nm, frequency-doubled, Q-switched
neodymium-doped yttrium aluminium garnet (Nd:YAG)
laser, SLT results in the selective absorption of energy by
pigmented cells in the trabecular meshwork and spares
adjacent cells and tissues from thermal energy damage
[8]. Compared to ALT, each SLT pulse delivers less than
0.1 % total energy and is eight orders of magnitude
shorter in duration.
SLT was initially studied as a secondary modality in
cases of failed medical therapy or prior ALT [9–12].
More recently, SLT has proven effective as a primary
treatment in OAG with minimal side effects or com-
plications [13–16]. It has also been used as a replace-
ment for medical therapy in controlled open-angle
glaucoma [17].
Because of the very short pulse duration of SLT (com-
pared to thermal relaxation time of the tissue), the adja-
cent tissues do not absorb the laser energy, and the
spread of heat damage is minimized. The significant de-
crease in tissue disruption allows for the potential of
retreatment with SLT.
The most widely used definition of repeat laser trabe-
culoplasty is applying laser to the same area that has
been treated previously. In most cases of SLT, this repre-
sents an initial 360-degree treatment followed by a sec-
ond 360-degree treatment. Due to the coagulative effect
of argon laser on the trabecular meshwork, ALT has
shown limited success in repeated treatments [18–21].
Retreatment is usually applied when an initial treat-
ment has been successful and the effect diminishes over
time. However, it is sometimes applied when the initial
response is not enough to reach target IOP levels. In our
study, we considered the first scenario. Repeat treatment
should be differentiated from augmentation or sequen-
tial treatment. Treating 180° followed by laser to the
remaining 180° may be termed augmentation of treat-
ment. Finally, SLT performed after ALT (or any laser tra-
beculoplasty procedure followed by treatment with a
different laser) should be differentiated as sequential
treatment with the two laser modalities identified.
We performed a multi-center, retrospective study of
repeat SLT in patients who had undergone a 360-degree
treatment, followed by a reduction of IOP response over
time, and who were then treated with a second laser. To
our knowledge, this is only the second report of repeat
SLT, but with a much larger cohort and longer follow
up. The larger numbers allow for several subanalyses,
such as matching for baselines, time between lasers, and
type of glaucoma medications, as well as a survival
analysis.
Methods
The inclusion criteria were primary or secondary open-
angle glaucoma, age greater than 18 years, and treatment
with 360-degree SLT (SLT 1) followed by retreatment of
360-degree SLT (SLT 2) more than 6 months later for
decrease of IOP control. A minimum follow-up time of
6 months after SLT 2 was also required for inclusion.
Exclusion criteria were uveitic, traumatic, or angle-
closure glaucoma, prior glaucoma surgery (except ALT),
corneal disease that may affect applanation tonometry,
aphakia, and systemic or ocular steroid use.
Data collection
Demographic information collected included age, gen-
der, race, and glaucoma diagnosis. All patients received a
complete ophthalmic exam prior to SLT, including cen-
tral corneal thickness measurement and optic nerve
head exam.
Baseline IOPs for both initial and repeat SLT were de-
fined as the average of two IOPs: the IOP at the visit
prior to the SLT and the pre-procedure IOP on the day
of laser. Preoperative baseline medication was defined as
the number of medications the patient was taking at the
time of the pre-operative IOP measurements. Fixed
combination medications were counted as two separate
glaucoma medications. Postoperative data was collected
at 1, 3, 6, and 12 months following both SLT treatments.
All IOPs were measured by a certified ophthalmic
technician or an ophthalmologist using a calibrated
Goldmann applanation tonometer.
SLT procedure
All initial and repeat SLT procedures were performed by
glaucoma specialists at referral glaucoma centers. Prior
to initiation of the study, the investigators met to agree
on a standardized laser technique to minimize the vari-
ation in power, number, and location of laser spots. Eyes
were treated with topical tetracaine or proparacaine
hydrochloride and all were pretreated with apraclonidine
1.0 % or brimonidine 0.15 % or 0.1 %. The protocol was
similar to that initially described by Latina et al. [12].
The Q-switched frequency-doubled 532 nm Nd:YAG
laser (Lumenis Selecta SLT Laser, Lumenis Inc., Santa
Clara, CA) was used with a wavelength of 532 nm, with
a pulse duration of 3 ns. The number of shots ranged
from 80 to 132 non-overlapping laser spots over 360° of
trabecular meshwork (TM). The energy level for treat-
ment was adjusted between 0.6 and 1.4 mJ to cause for-
mation of small cavitation energy bubbles during at least
50 % of shots.
Outcome measures
Two definitions of success were used. The first and more
stringent is similar to the Tube versus Trabeculectomy
Study [22]: the IOP had to be between 5 and 21 mmHg
while demonstrating at least a 20 % IOP decrease from
baseline and while avoiding the addition of any glaucoma
Francis et al. BMC Ophthalmology  (2016) 16:128 Page 2 of 7
medications or glaucoma procedures. Definition 2 was
IOP 5 to 21 mmHg, along with either an IOP lowering by
at least 20 %, or reduction of glaucoma medication use
and without the need for glaucoma surgery or laser.
Only one eye from each qualifying subject was entered
into the analysis. If both eyes qualified, then one was
randomly chosen for inclusion. The statistical analysis
was performed with SAS V9.2 (SAS Institute, Cary NC),
and the accepted level of significance for all tests was α
= 0.05. Student’s t-test was used to compare mean mea-
sures between SLT1 and SLT2 and a paired t-test was
used to compare mean change from baseline within SLT
1 or 2. Independent sample t-tests and chi-squared tests
were used to compare measures between subgroups.
Survival analysis was done with the Kaplan-Meier
method and compared using the log rank test. The study
was powered to detect a difference in mean IOP reduc-
tion between the two treatment arms (SLT1 vs SLT2) of
1.7 mmHg or greater, using a power of 80 % and alpha
0.05.
For patients lost to follow-up, IOP measurements and
glaucoma medication numbers were included only dur-
ing the time they were still in the study. Patients were
followed and analyzed to the point of failure or until the
most recent follow-up recorded.
Results
One hundred thirty-seven eyes of 137 patients qualified
for inclusion in this study. The demographics are pre-
sented in Table 1. The mean age was 72.5 +/− 11.9 years,
with the majority of patients being Caucasian (76.5 %).
Most patients had primary open-angle glaucoma
(80.3 %). The number of glaucoma medications at base-
line was 2.2 +/− 1.2 for SLT 1 and 2.1 +/− 1.3 for SLT 2.
The baseline IOP was 20.3 +/− 5.2 for SLT 1 and 19.4
+/− 5.0 for SLT 2 (p = 0.03). At 6 months, the IOP de-
creased to 16.3 +/− 4.3 and 16.3 +/− 4.8 and at
12 months to 16.4 +/− 3.9 and 16.7 +/− 4.7, respectively
(see Table 2).
The success rate for SLT 1 with definition 1 was 55 %
at 6 months and 34 % at 12 months (see Fig. 1). Using
definition 2, which includes medication reduction, for
SLT 1, the rate of success was 65 % at 6 months and
44 % at 12 months. For SLT 2, the success rate with def-
inition 1 was 37 % at 6 months and 19 % at 12 months.
For definition number two for SLT 2, the success rate
was 48 % at 6 months and 27 % at 12 months.
A sub-analysis was performed with case matching by
baseline IOP. This was done due to the lower baseline
IOP noted prior to SLT2 compared to prior to SLT1 in
the full group analysis. These 62 patients had a baseline
IOP prior to SLT 1 that was similar (within 2 mmHg) to
the IOP noted prior to SLT 2 (see Table 3). In this sub-
set, the mean IOP prior to SLT 1 was 18.7 +/− 3.8, and
the mean prior to SLT 2 was 18.7 +/− 3.5. After
6 months the IOP decreased to 16.0 +/− 4.3 vs 15.3 +/−
3.8 after SLT 2. Twelve months after SLT 1 the mean
IOP was 15.8 +/− 3.3 versus 16.6 +/− 4.5 12 months
after SLT 2. The success rates were also similar between
SLT 1 and 2 in this subgroup. For the first definition, the
success of SLT 1 was 43 % at 6 months and 20 % at
12 months, and for SLT 2 it was 44 and 20 %. Using the
second definition, the success of SLT 1 was 57 % at
6 months and 33 % at 12 months, and for SLT 2 it was
52 and 28 %, respectively.
Another sub-analysis compared two groups stratified
by the amount of time between SLT 1 and 2: less than
1 year versus greater than 1 year (see Table 4). Using the
first definition, the success rates for cases where SLT 2
was performed at least 1 year after SLT 1 were 30 % at
6 months and 14 % at 12 months. When SLT 2 was per-
formed within 1 year of SLT 1, the success rates were
higher at 59 % at 6 months and 35 % at 12 months (p =
0.006). Using definition 2, the success rates were again
higher if SLT 2 occurred within 1 year after SLT 1.
When SLT 2 was performed 1 year or more after SLT 1,
the success rates were 41 % at 6 months and 22 % at
12 months. For less than a 1-year interval, the suc-
cess was 70 % at 6 months and 45 % at 12 months
(p = 0.01).
The effect of glaucoma medications was also studied.
Patients were divided into those using prostaglandin
analog (PGA) medications after laser and those not
using them. There was a trend toward higher success
Table 1 Patient demographics for repeat selective laser
trabeculoplasty
Number of eyes 137












Primary open-angle glaucoma 80.3 %
Pseudoexfoliation glaucoma 12.4 %
Pigmentary glaucoma 4.4 %
Ocular hypertension 1.5 %
Juvenile open angle glaucoma 1.5 %
Previous argon laser trabeculoplasty 8.8 %
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rates in patients not using a PGA. The success of SLT 2
for patients using a PGA was 36 % at 6 months and
18 % at 12 months, versus 44 and 25 %, respectively, for
those not using them. Using definition number two, the
success rates were 47 and 24 % for PGA and 56 and
42 % for no PGA. These differences were not statistically
significant when compared using the log rank test for
survival curve comparison (p = 0.44, p = 0.22).
The rate of success for SLT2 was also stratified by
whether SLT 1 met the success criteria, but there was no
difference in the success of SLT 2 (survival curves not
shown).
Discussion
Sequential treatment with SLT after ALT has demon-
strated success since the initial clinical study by
Latina et al. [12]. The study included two SLT treat-
ment arms: one with uncontrolled IOP on maximal
medical therapy, and the second with uncontrolled
IOP with prior failed ALT. The sequential treatment
group (ALT then SLT) had a mean IOP reduction of
3.8 mmHg from a baseline of 25.3 mmHg, which was
comparable to the group without any prior laser
treatment.
The first published clinical study on the success of re-
peat SLT was by Hong et al. [23]. In this retrospective
review, 44 eyes of 35 open-angle glaucoma patients with
a prior 360-degree SLT that was successful for 6 months
but then lost efficacy were treated with a repeat 360-
degree SLT. The IOP was recorded prior to the proced-
ure and 1–4 weeks, 1–3 months, and 5–8 months after
treatment. The reduction in IOP after SLT 1 and SLT 2
was not statistically different at any time point, except at
1 to 3 months, when reduction was greater after SLT 1.
Using a definition of success of at least a 20 % IOP re-
duction, the authors found no difference between SLT 1
and 2. They also found no difference whether the SLT
was repeated within 6–12 months of SLT 1 versus after
12 months. They concluded that repeat 360-degree SLT
is safe and effective after an initially successful 360-









20.3 (5.2) 19.4 (5.0) 0.03
6–12 months
(n = 130,119)
16.3 (4.3) 16.3 (4.8) 0.86
12–15 months
(n = 100,99)
16.4 (3.9) 16.7 (4.7) 0.24
IOP 6–12 months 4.1 (4.8)* 2.9 (4.7)* 0.04
decrease 12–15 months 3.5 (4.7)* 2.2 (4.5)* 0.005
IOP % 6–12 months 17.7 (19.8)* 14.7 (24.2)* 0.32
reduction 12–15 months 14.5 (23.4)* 10.9 (22.2)* 0.11






















Fig. 1 Success of selective laser trabeculoplasty 2 = intraocular pressure (IOP) lowered 20 % or more, and IOP between 5 and 21 mmHg, with
no additional glaucoma medications or IOP lowering procedures (Tube versus Trabeculectomy Study criteria)
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degree SLT has lost efficacy, and that this may be ac-
complished as early as 6 months after the initial laser.
Our study had a similar design with some notable
exceptions. The number of subjects in our study was sig-
nificantly greater, and our study had longer follow-up.
We reported only data from one eye of each patient in
order to reduce any bias. With the larger sample size, we
were able to perform several subanalyses, including
case-matching and analyzing the length of time between
laser treatments and type of medication use. The multi-
center design has the drawback of a non-standardized
procedure and patient treatment protocol. However, it
also allows for greater numbers of subjects and enhances
the statistical analysis. Our study was retrospective ra-
ther than prospective, with the limitations inherent to
this design such as investigator bias, non-standardization
of treatment and data collection, and lack of a control
group.
We elected to include patients that had prior ALT in
our analysis. This scenario is becoming increasingly ap-
parent in clinical practice, as many patients that had ini-
tial laser trabeculoplasty with ALT have also now had
SLT followed by repeat SLT. Therefore, we included this
group in order to extend the applicability of results to
patients that had prior ALT, not just those with only
SLT. We performed an analysis of the main outcome
measures without this group, and did not see any differ-
ence in the reduction of IOP or in the comparison of
IOP levels or reduction after either SLT1 or SLT2.
The success criteria applied for this study are quite
stringent and are the same as those used to determine
the success of incisional filtration surgery in the Tube
versus Trabeculectomy Study [24]. We felt that this
criteria was best because it is evidence-based and
incorporates a percentage IOP decrease. Since laser
trabeculoplasty is often used to reduce dependence on
Table 3 Significance of within treatment change, **p < 0.001, *p < 0.01. IOP intraocular pressure, SLT selective laser trabeculoplasty
SLT1 Mean (standard deviation) SLT2 Mean (standard deviation) Paired t-test p-value
IOP Baseline
(n = 62)
18.7 (3.8) 18.7 (3.5) 0.96
6–12 months
(n = 61,52)
16.0 (4.3) 15.3 (3.8) 0.58
12–15 months
(n = 49,44)
15.8 (3.3) 16.6 (4.5) 0.33
IOP 6–12 months 2.8 (3.7)** 3.4 (3.6)** 0.64
decrease 12–15 months 2.5 (3.0)** 1.9 (3.5)* 0.38
IOP % 6–12 months 17.7 (19.8)* 14.7 (24.2)* 0.32
reduction 12–15 months 12.7 (15.1)** 11.3 (19.7)* 0.74
Table 4 SD standard deviation, IOP intraocular pressure, SLT selective laser trabeculoplasty. Significance of within treatment change,
**p < 0.001, *p < 0.01. p-values in the right hand column reflect comparisons for baseline and treated IOP between SLT1
(<12 months in between treatments) and SLT1 (≥12 months between treatments, and SLT2 (<12 months in between treatments)
and SLT2 (≥12 months between treatments)
Interval between SLT1 and SLT2
≥ 12 months
Interval between SLT1 and SLT2
< 12 months
SLT1 Mean (sd) SLT2 Mean (sd) p SLT1 vs SLT2 SLT1 Mean (sd) SLT2 Mean (sd) p SLT1 vs SLT2 p-value
IOP Baseline
(n = 104,33)




15.3 (3.3) 16.4 (4.8) 0.03 20.0 (5.4) 16.2 (5.1) 0.004 <0.001
0.82
12–15 months
(n = 97,80,13, 19)
















12–15 months 15.0 (23.5)** 8.9 (20.9)** 0.09 0.2 (12.8) 19.4 (25.8)* 0.66 0.28
0.06
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glaucoma medications rather than to eliminate the need
for medications, we added the second success definition,
which includes reduction of medications, while main-
taining IOP, as a success. One limitation of medication
reduction as an outcome measure (in the absence of a
washout) is that it does not account for some of the
medications having already lost efficacy prior to
treatment.
The data from our study did support the findings of
the initial repeat SLT study. Repeat 360-degree SLT re-
sulted in a reduction of IOP to a similar level, although
the magnitude of decrease was greater for SLT 1 due to
a higher baseline. The differences in baseline likely re-
flect clinical practice, where a surgeon will generally not
wait until the IOP has returned all the way to the initial
pre-treatment baseline but will perform a second treat-
ment when the IOP begins to rise. However, when pa-
tients with similar baselines were examined, the
amounts of IOP lowering and success rates were very
similar.
Interestingly, a shorter time period between the first
and second SLT resulted in statistically significant higher
success rates for the effect of a repeat laser. This was
true for both definitions of success used. We had initially
hypothesized that a longer time period between lasers
indicated a more effective first treatment and would pre-
dict a greater success for the repeat SLT.
The analysis of medications used (using a PGA versus
not) showed no significant difference. We hypothesized
that there may be a greater effect of SLT and repeat SLT
in those not using a PGA. This was due to the data from
Alvarado et al. showing a similar mode of action of PGA
drugs and SLT laser, with both exerting an effect on
Schlemm’s canal endothelial cells [25, 26]. There was a
small trend towards greater efficacy of SLT without PGA
medications, and perhaps larger numbers of patients
may show a difference. Our study was not powered to
answer this specific question.
Conclusions
In conclusion, selective laser trabeculoplasty is success-
ful in the initial and repeat treatment of open-angle
glaucomas. This scenario has included patients who have
had an initial successful treatment with 360-degree SLT
lasting at least 6 months, with the effect wearing off over
time. A second application of 360-degree SLT showed
successful lowering of IOP or medications in these cases.
This is a distinct advantage over argon laser trabeculo-
plasty (ALT), in which repeated treatments result in pro-
gressive damage to the trabecular meshwork and
diminishing success. The difference may be attributable
to the selective targeting of pigmented cells with SLT
and the lack of coagulative damage to the outflow tract.
Abbreviations
ALT, argon laser trabeculoplasty; IOP, intraocular pressure; Nd:YAG,
neodymium-doped yttrium aluminium garnet; OAG, open-angle glaucoma;
PGA, prostaglandin analog
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